How AI Search Is Recommending Peptide API Manufacturing: Monthly Trends

Executive Summary

The category leadership position widened substantially in October 2026. Bachem leads Peptide API Manufacturing at 67.0% valid recommendation coverage, up 24.8 points from 42.2% in July 2026, and the benchmark flags that baseline-to-current move as significant. The gap to second-place AmbioPharm is 44.5 points, the widest leader-to-runner-up separation in the tracked series.

Bachem is also the only brand the benchmark flags as a significant riser this month. Its gain was concentrated in placement rather than presence: coverage rose 24.8 points from July, top-three rate rose 24.9 points from 35.6% to 60.5%, and rank-one rate rose 21.8 points from 22.2% to 44.0%, with raw mention presence nearly flat. The move from September to October was the largest single-month change in the series, up 30.8 points from 36.2%.

The sharpest decliner against baseline is CSBio, down 2.1 points from 3.1% in July to 1.0% in October, with three consecutive monthly declines and a top-three rate that fell to 0.0% from 1.8%. That cumulative move remains inside normal variation.

Against September 2026, six of the seven tracked brands improved, and five of those prior-to-current gains were large enough for the benchmark to flag as significant: Bachem up 30.8 points, AmbioPharm up 12.0 points, PolyPeptide Group up 8.7 points, CPC Scientific up 7.5 points, and CordenPharma Peptides up 4.8 points. The category recorded movement rather than stability, driven by a broad October recovery after a September trough rather than by Bachem alone.

Each monthly run begins with the benchmark's full prompt collection across the defined AI/search surface universe. The July 2026 run collected 280 prompt-surface observations (194 unique questions); 280 mentioned a tracked brand or competitor, 253 were relevant and 27 were irrelevant, leaving 225 qualified observations. The October 2026 run collected 306 prompt-surface observations (203 unique questions); 306 mentioned a tracked brand or competitor, 268 were relevant and 38 were irrelevant, leaving 200 qualified observations. For comparison, the August 2026 run collected 340 observations (241 unique questions) and the September 2026 run collected 373 observations (236 unique questions), each producing 257 qualified observations. The public metrics use the 200 qualified observations that survive both qualification stages in October.

Key Findings

AI Response Inconsistency Alerts

The benchmark's October conflict scan detected 1 high-severity factual inconsistency across 2 AI platforms. The conflict is a direct factual contradiction between platforms answering the same question, not a difference in emphasis or recommendation ordering.

AmbioPharm

One high-confidence conflict concerns AmbioPharm's ownership and acquisition status, in which the two platforms gave directly incompatible answers. When asked, "What are the biggest peptide companies?", Gemini stated that AmbioPharm is listed as an independent major global peptide manufacturer, citing a market research company ranking page, Bachem's corporate site, and a third-party ranking article. ChatGPT stated on the same question that CordenPharma completed its acquisition of AmbioPharm in August 2026, so AmbioPharm is no longer independent. ChatGPT's answer referenced a market research report, CordenPharma's own announcement page, and a news wire report covering a related transaction.

The two claims cannot both be true. A company cannot simultaneously be an independent peptide manufacturer and a business already acquired by another manufacturer. The source page flagged at high confidence is CordenPharma's own announcement stating that it completed the acquisition of US-headquartered peptide CDMO AmbioPharm, which sits on the ChatGPT side of the conflict. This is an ownership-status fact of the kind buyers encounter early when they screen suppliers, so the same question currently returns materially different corporate structures depending on which surface a buyer uses.

Benchmark Context

Questions This Section Answers

• How many prompt-surface observations qualified for the October 2026 peptide API manufacturing benchmark?
• Why is the qualified observation count lower in October even though more prompts were collected?

The report separates the raw collection universe from the qualified analysis set. Brand-level recommendation percentages are calculated within the qualified benchmark set.

Benchmark-Level Metrics

The following category-wide figures summarize how overall answer composition moved between the July and October benchmark runs.

The September 2026 run sat between these two points, with recommendation-shaped answers at 21.4% and valid recommendation shortlist share at 32.3% on 257 qualified observations. October reversed that September contraction: fewer observations were qualified, but a much larger share of them were recommendation-shaped, and the leader converted that mix change into a substantially larger share of the recommendation pool.

AI Recommendation Trend

Questions This Section Answers

• Which peptide API manufacturers gained or lost recommendation coverage between July and October 2026?
• How much did Bachem's lead over the rest of the category widen against baseline?
• Which brands' month-over-month moves stayed inside normal variation?

Leadership held while the leader's margin widened sharply

Bachem extended its lead rather than defending it, and the rest of the field moved up off a weak September base without closing the distance to first place.

Against baseline, only Bachem's move exceeded the range the benchmark treats as normal month-to-month variation. Every other brand's baseline-to-current change stayed inside that range, so the category-level improvement reflects a combination of several smaller movements plus one outsized leader gain, not a uniform shift across the field.

What Changed This Month

Questions This Section Answers

• What drove Bachem's jump to 67.0% recommendation coverage in October?
• How did AmbioPharm recover coverage while its raw mention presence kept falling?
• What do the gains for PolyPeptide Group, CPC Scientific, and CordenPharma Peptides on small bases actually signal?

Bachem converts presence into recommendation dominance

Bachem's valid recommendation coverage rose from 42.2% in July 2026 to 67.0% in October 2026, a 24.8-point gain the benchmark flags as significant. The move from September to October was sharper still, up 30.8 points from 36.2%, the largest single-month change recorded for any brand in the tracked series. This is a one-month shift, not an established multi-month trend.

The change sits almost entirely in placement. Bachem's top-three rate rose 24.9 points from 35.6% to 60.5%, and its rank-one rate rose 21.8 points from 22.2% to 44.0%. The brand delivered 134 valid recommendations in October with 88 rank-one placements, against 93 valid recommendations and 38 rank-one placements in September.

The distinction to notice: raw mention presence barely moved, from 91.1% in July to 92.5% in October and 92.6% in September. Bachem was already visible in nearly every answer before this gain. What changed is how often those appearances converted into a recommendation and into first position. With 134 of 138 valid recommendation shortlist entries in the category and 88 rank-one placements, the October answer pool is close to a single-name outcome at the top of the recommendation set.

Highest-priority diagnostic: Which surfaces and prompt types drove the September-to-October jump in Bachem's rank-one conversions, and whether that concentration reflects a sourcing shift or a response-mix shift.

AmbioPharm recovers coverage while its presence keeps sliding

AmbioPharm's valid recommendation coverage rose from 10.5% in September 2026 to 22.5% in October 2026, a 12.0-point gain the benchmark flags as significant, taking the brand back to roughly its July level of 21.8%. Against baseline the net move is up 0.7 points, inside normal variation. This is a one-month recovery, not a trend.

Placement improved modestly on a larger base. The top-three rate moved from 15.1% in July to 18.0% in October, up 2.9 points and inside normal variation, while the rank-one rate moved from 1.8% to 2.0%. The brand delivered 45 valid recommendations in October from 74 present observations, with 4 rank-one placements, after 27 valid recommendations from 101 present observations in September.

The distinction to notice: coverage recovered while raw mention presence kept falling, from 42.2% in July to 37.0% in October and 39.3% in September. AmbioPharm is appearing in fewer answers overall but converting a larger share of the appearances it does get into recommendations. A separate finding in this report also applies here: the benchmark's conflict scan found Gemini and ChatGPT giving contradictory answers about whether AmbioPharm remains independent or has been acquired by CordenPharma.

Highest-priority diagnostic: Whether the ownership contradiction affects the subset of answers where AmbioPharm is recommended, and which prompts still place it in top-three positions.

PolyPeptide Group leads the mid-tier recovery

PolyPeptide Group's valid recommendation coverage rose from 5.8% in September 2026 to 14.5% in October 2026, an 8.7-point gain the benchmark flags as significant, and up 4.7 points against the July baseline of 9.8%, which stays inside normal variation. The brand now ranks 5th, up from 3rd in September's ordering.

Placement moved with coverage but not significantly against baseline. The top-three rate rose 4.9 points from 7.6% in July to 12.5% in October, and the rank-one rate moved from 0.0% to 1.0%. PolyPeptide Group delivered 29 valid recommendations in October from 47 present observations, with 2 rank-one placements, after 15 valid recommendations in September.

The distinction to notice: raw presence moved only 1.7 points against baseline, from 21.8% to 23.5%, while coverage rose 4.7 points. The brand converted a modestly larger presence into a meaningfully larger recommendation share, which is the pattern inverse to its September result, when presence rose and recommendations fell.

Highest-priority diagnostic: Which prompt types PolyPeptide Group now converts that it did not convert in September, and whether the recovery is concentrated on a small number of questions.

CPC Scientific and CordenPharma Peptides lift off low bases

CPC Scientific's valid recommendation coverage rose from 5.5% in September 2026 to 13.0% in October 2026, a 7.5-point gain the benchmark flags as significant, and up 5.4 points against the July baseline of 7.6%, inside normal variation. Its top-three rate rose 4.9 points from 3.1% in July to 8.0% in October, while its rank-one rate slipped 1.3 points from 1.8% to 0.5%. The brand delivered 26 valid recommendations in October, with 1 rank-one placement.

CordenPharma Peptides rose from 2.7% in September 2026 to 7.5% in October 2026, a 4.8-point gain the benchmark flags as significant, and up 3.9 points against the July baseline of 3.6%, inside normal variation. Its top-three rate rose 4.2 points from 1.3% to 5.5%, and its rank-one rate stayed flat at 0.0%. The brand delivered 15 valid recommendations in October from 25 present observations, with no rank-one placements.

The distinction to notice: both brands now hold coverage built on counts of 26 and 15 valid recommendations respectively, and CordenPharma holds zero rank-one positions. Movement of this size on bases this small should be read as directional. CordenPharma's net sentiment score fell from 1.0 in July to 0.6 in October, the lowest recorded among tracked brands this month, so its coverage gains are not matched by sentiment gains.

Highest-priority diagnostic: Whether these gains hold in November, and for both brands, which prompt types produced the incremental recommendations.

Biosynth Peptide Division and CSBio sit apart from the category recovery

Biosynth Peptide Division's valid recommendation coverage moved from 12.4% in July 2026 to 11.0% in October 2026, down 1.4 points against baseline, inside normal variation, with a 4.8-point September-to-October rise from 6.2% that stayed inside normal variation. Raw mention presence fell sharply against baseline, down 11.2 points from 26.2% to 15.0%. The brand delivered 22 valid recommendations in October from 30 present observations, with 2 rank-one placements, after 16 valid recommendations in September.

CSBio's valid recommendation coverage fell from 3.1% in July 2026 to 1.0% in October 2026, down 2.1 points, inside normal variation but the third consecutive monthly decline. Its top-three rate fell 1.8 points from 1.8% to 0.0%, and its rank-one rate stayed flat at 0.0%. The brand delivered 2 valid recommendations in October from 3 present observations, after 4 valid recommendations in September.

The distinction to notice: Biosynth is one of only two brands whose baseline-to-current coverage moved down, and its presence loss is the larger figure, not its coverage loss, meaning it is exiting the answer pool more than it is being demoted within it. CSBio now sits on 2 valid recommendations from 3 present observations, the narrowest base in the category. Percentages built on counts that small change meaning with a single response, and the three-month decline is a watch item rather than a significant move.

Highest-priority diagnostic: For Biosynth, which surfaces stopped surfacing it and whether the loss tracks its October presence decline. For CSBio, which prompts still return it as a valid recommendation at all.

Buyer-Intent Interpretation

Questions This Section Answers

• Which buyer-intent clusters produced qualified observations in October 2026?
• What can the benchmark not yet answer about pricing and head-to-head supplier comparisons?

In October 2026, all 200 qualified observations fell into the Brand Recommendation cluster. The pricing and value cluster and the multi-brand comparison cluster contained zero qualified observations. The public benchmark's evidence therefore remains concentrated on direct recommendation queries, and it cannot yet answer how AI systems handle price sensitivity, value comparisons, or head-to-head supplier trade-offs in this vertical.

The response-type mix shows some comparison activity beneath the surface, with 11 comparison analysis responses in October alongside 36 ranked list responses and 97 recommendation shortlists. Those did not form qualified clusters, so the commercial questions the benchmark can currently answer are about who gets recommended, not which supplier wins on price or on direct comparison.

The commercial implication: the benchmark's public evidence answers who AI systems name when buyers ask for a peptide API manufacturer, but not which supplier prevails on cost, value, or head-to-head merit.

Brand Opportunity Summary

The benchmark identifies where attention is warranted across all seven tracked brands; a company-level analysis is needed to explain why the movements occurred.

Evidence Behind the Benchmark

The aggregate metrics are built from prompt-level observations (query, surface, recommendation outcome, rank, sentiment, and citations where exposed). Company-level analysis can go deeper into prompt, competitor, surface, and evidence patterns. Source presence is not automatically treated as proof of causation.

About This Benchmark

This report is part of the CiteWorks Studio AI Visibility Industry Market research program.

• AI Visibility Industry Market
• AI Visibility Industry Market Methodology
• AI Visibility Industry Market Metrics
• AI Visibility Industry Market Standards

Report-Specific Interpretation Notes

• Small counts: CSBio holds 2 valid recommendations, CordenPharma Peptides 15, and CPC Scientific 26 in October. Percentage movement for these brands rests on a narrow base and should be read with caution.
• Qualified denominator: brand percentages are calculated against the 200 qualified observations in October, not the 306 raw prompts collected or the 268 relevant prompts.
• Directional analysis: month-over-month movement identifies changes worth investigating; it does not by itself establish the cause of those changes.
• Concentration: Bachem holds 134 of the 138 valid recommendation shortlist entries recorded in October, so category-level recommendation share is dominated by one brand's conversion rate this month.

Next Step

The Public Benchmark Shows Where a Brand Is Winning or Losing. A Company-Level Audit Shows Why.

Beneath the aggregate percentages sit the questions that determine commercial outcomes: which high-intent prompts a brand wins, which competitor takes the recommendation when a brand loses, what attributes AI systems associate with each supplier, and which external sources shape those answers. The October 2026 data shows Bachem extending its lead on a placement surge, five other brands recovering from a September trough on small bases, CSBio on three consecutive declines, and a flagged factual conflict about AmbioPharm's ownership status, but the benchmark cannot say why any of these movements happened or which specific queries changed.

A company-specific AI visibility audit maps those prompt, surface, competitor, ranking, sentiment, and evidence-source patterns into a prioritized visibility strategy. For leadership teams in peptide API manufacturing, understanding which named supplier AI systems put first, and what evidence is associated with that outcome, is the foundation for protecting or improving position.

Request an AI visibility audit